• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗磷脂抗体暴露时间而非年龄是血栓形成的危险因素:一项回顾性单中心观察研究。

Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study.

机构信息

Department of Internal Medicine, Hospital Universitario Araba, Calle Jose Atxotegi s/n, 01009, Vitoria, Spain.

Clinical Research Unit, BioAraba Health Research Institute, Hospital Universitario Araba, Calle Jose Atxotegi s/n, 01009, Vitoria, Spain.

出版信息

Rheumatol Int. 2018 Feb;38(2):229-238. doi: 10.1007/s00296-017-3878-z. Epub 2017 Nov 10.

DOI:10.1007/s00296-017-3878-z
PMID:29124399
Abstract

To investigate the association of age and other factors with thrombosis risk in antiphospholipid antibody (aPL) carriers, a retrospective observational study was conducted in a cohort of patients with medium-high aPL titres recruited in a tertiary care hospital. Assuming an age difference of 9.8 years between patients with and without thrombosis, we estimated that a sample size of 70 participants was required. Several variables besides age including gender, vascular risk factors, inherited thrombophilias, non-thrombotic clinical manifestations, laboratory parameters, aPL profile, length of aPL exposure, antithrombotic drugs and partial aPL score were assessed by univariate analysis followed by multivariate logistic regression. Outcomes were analysed by whether thromboses occurred before (model 1) or after (model 2) aPL detection. Seventy patients [50 females; median (interquartile range) baseline age: 46.99 (39.39-66.20) years] were followed for 2.59 (0.67-5.86) years. Overall, 18 and 5 thromboses were diagnosed applying models 1 and 2, respectively. Time to thrombosis after aPL detection was 2.10 (1.03-8.24) years. Age did not differ between patients with and without thrombosis using models 1 (p = 0.92) or 2 (p = 0.67). Instead, we identified other predictors of thrombosis, namely, lack of thromboprophylaxis [odds ratio (OR) 13.50, 95%  confidence interval (95% CI) 1.02-178.05, p = 0.048] and length of aPL exposure (OR 1.41, 95% CI 1.04-1.92, p = 0.026) in model 2, while lupus anticoagulant showed a tendency to increase the risk (OR 7.10, 95% CI 0.86-58.78, p = 0.069) in model 1. Unlike age, lack of thromboprophylaxis, prolonged aPL exposure and lupus anticoagulant may increase the risk of thrombosis in aPL carriers.

摘要

为了研究年龄和其他因素与抗磷脂抗体(aPL)携带者血栓形成风险的关系,对一家三级医院中中高滴度 aPL 患者队列进行了回顾性观察研究。假设患有血栓形成和不患有血栓形成的患者之间的年龄差异为 9.8 岁,我们估计需要 70 名参与者的样本量。除年龄外,还评估了性别、血管危险因素、遗传性血栓形成倾向、非血栓形成临床表现、实验室参数、aPL 谱、aPL 暴露时间、抗血栓形成药物和部分 aPL 评分等多个变量。通过单变量分析评估这些变量,然后进行多变量逻辑回归。通过血栓形成是否发生在(模型 1)或发生在(模型 2)aPL 检测之前来分析结果。70 名患者[50 名女性;中位(四分位间距)基线年龄:46.99(39.39-66.20)岁]随访 2.59(0.67-5.86)年。总体而言,应用模型 1 和模型 2 分别诊断了 18 例和 5 例血栓形成。在 aPL 检测后发生血栓形成的时间为 2.10(1.03-8.24)年。应用模型 1(p=0.92)或模型 2(p=0.67),患者有或无血栓形成之间的年龄无差异。相反,我们确定了其他血栓形成的预测因素,即在模型 2 中,缺乏血栓预防(比值比[OR]13.50,95%置信区间[95%CI]1.02-178.05,p=0.048)和 aPL 暴露时间(OR 1.41,95%CI 1.04-1.92,p=0.026),而狼疮抗凝剂显示出增加风险的趋势(OR 7.10,95%CI 0.86-58.78,p=0.069)在模型 1 中。与年龄不同,缺乏血栓预防、aPL 暴露时间延长和狼疮抗凝剂可能会增加 aPL 携带者发生血栓形成的风险。

相似文献

1
Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study.抗磷脂抗体暴露时间而非年龄是血栓形成的危险因素:一项回顾性单中心观察研究。
Rheumatol Int. 2018 Feb;38(2):229-238. doi: 10.1007/s00296-017-3878-z. Epub 2017 Nov 10.
2
Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity.在一项针对无血栓形成或产科并发症病史患者的长期随访研究中,持续性三联抗磷脂抗体阳性是首次发生血栓形成的强烈危险因素。
Lupus. 2017 Feb;26(2):163-169. doi: 10.1177/0961203316657433. Epub 2016 Jul 20.
3
Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.无症状携带者中持续性抗磷脂抗体(aPL)作为未来血栓形成事件的危险因素:一项全国性前瞻性研究。
Lupus. 2014 Dec;23(14):1468-76. doi: 10.1177/0961203314545410. Epub 2014 Aug 27.
4
Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.抗磷脂抗体阳性狼疮患者血栓形成并发症发生的危险因素分析。
Lupus. 2007;16(1):39-45. doi: 10.1177/0961203306074767.
5
Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria.血小板减少症作为无疾病标准的抗磷脂抗体患者的血栓形成危险因素。
Med Clin (Barc). 2017 May 10;148(9):394-400. doi: 10.1016/j.medcli.2016.11.026. Epub 2017 Jan 30.
6
Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.抗磷脂抗体与系统性红斑狼疮的非血栓形成表现
Lupus. 2018 Apr;27(4):665-669. doi: 10.1177/0961203317734924. Epub 2017 Oct 19.
7
Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study).抗磷脂综合征与血栓复发患者:一项真实世界观察(皮埃蒙特队列研究)
Lupus. 2016 Apr;25(5):479-85. doi: 10.1177/0961203315617538. Epub 2015 Dec 8.
8
Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study.抗磷脂抗体患者血小板计数的血栓风险分层:一项纵向研究。
J Thromb Haemost. 2017 Sep;15(9):1782-1787. doi: 10.1111/jth.13763. Epub 2017 Aug 5.
9
Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.高滴度抗心磷脂抗体和多种抗磷脂抗体患者的血栓栓塞风险
Thromb Haemost. 2003 Jul;90(1):108-15.
10
Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers.识别小儿抗磷脂抗体携带者中动脉和静脉血栓形成的其他危险因素。
Lupus. 2021 Apr;30(5):828-832. doi: 10.1177/09612033211002256. Epub 2021 Mar 18.

引用本文的文献

1
Evaluation of Frequency, Clinical Correlation, and Antibodies Confirmation Profile in Patients with Suspected Antiphospholipid Syndrome.疑似抗磷脂综合征患者的频率、临床相关性及抗体确认情况评估
TH Open. 2021 Oct 19;5(4):e470-e478. doi: 10.1055/s-0041-1736289. eCollection 2021 Oct.

本文引用的文献

1
Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence.原发性抗磷脂综合征中抗磷脂抗体的消失:血栓复发。
Autoimmun Rev. 2017 Apr;16(4):352-354. doi: 10.1016/j.autrev.2017.02.004. Epub 2017 Feb 13.
2
Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio.抗磷脂抗体与复发性血栓形成事件:持续性与组合情况
Cerebrovasc Dis. 2015;40(5-6):293-300. doi: 10.1159/000441362. Epub 2015 Oct 29.
3
Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry.
系统性红斑狼疮中的心血管事件:来自西班牙RELESSER注册研究的全国性研究
Medicine (Baltimore). 2015 Jul;94(29):e1183. doi: 10.1097/MD.0000000000001183.
4
The challenge of bleeding in antiphospholipid antibody-positive patients.抗磷脂抗体阳性患者的出血挑战。
Curr Rheumatol Rep. 2015 Feb;17(2):7. doi: 10.1007/s11926-014-0481-0.
5
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant.孤立性狼疮抗凝物携带者首次血栓栓塞事件的发生率。
Thromb Res. 2015 Jan;135(1):46-9. doi: 10.1016/j.thromres.2014.10.013. Epub 2014 Oct 22.
6
Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36.抗磷脂(休斯)综合征:使用SF-36量表对人群及健康相关生活质量的描述
Lupus. 2015 Feb;24(2):174-9. doi: 10.1177/0961203314551809. Epub 2014 Sep 19.
7
Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.无症状携带者中持续性抗磷脂抗体(aPL)作为未来血栓形成事件的危险因素:一项全国性前瞻性研究。
Lupus. 2014 Dec;23(14):1468-76. doi: 10.1177/0961203314545410. Epub 2014 Aug 27.
8
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.第十四届抗磷脂抗体国际大会工作组。抗磷脂综合征实验室诊断及趋势报告。
Autoimmun Rev. 2014 Sep;13(9):917-30. doi: 10.1016/j.autrev.2014.05.001. Epub 2014 May 10.
9
The relationship between mean platelet volume and thrombosis recurrence in patients diagnosed with antiphospholipid syndrome.抗磷脂综合征患者平均血小板体积与血栓形成复发之间的关系。
Rheumatol Int. 2014 Nov;34(11):1599-605. doi: 10.1007/s00296-014-2996-0. Epub 2014 Mar 27.
10
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.抗磷脂综合征 10 年期间的发病率和死亡率:1000 例患者的多中心前瞻性研究。
Ann Rheum Dis. 2015 Jun;74(6):1011-8. doi: 10.1136/annrheumdis-2013-204838. Epub 2014 Jan 24.